Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data

Lefebvre, A.; Fiet, Caroline; Belpois-Duchamp, C.; Tiv, M.; Astruc, K.; Glélé, Ludwig Serge Aho

doi:10.1016/j.medmal.2014.08.005

Cited by 87 publications

(59 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ebola virus (EBOV), Tai Forest virus (TAFV), Reston virus (RESTV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are the virus making up the Ebolavirus genus [10]. EBOV and SUDV come as the most frequent outbreak-causing virus which has the case-fatality rate of 76 and 55% (CI 95%), respectively [11]. On the other hand, RESTV causes death in primates such as gorillas and chimpanzees but not known to have caused disease in humans [12,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioinformatics Approach to Screening and Developing Drug against Ebola

Tambunan¹,

Alkaff²,

Nasution³

2018

Advances in Ebola Control

View full text Add to dashboard Cite

Ebola is an acute disease causing hemorrhagic fever marked with high mortality rate. The patients who suffer from Ebola only receive palliative care because there is no available drug which can consistently cure this disease. To date, no cure has been found to treat this disease. Bioinformatics and computer-aided drug discovery and development (CADDD) are employed to utilize the readily available genomic and proteomic data and enhance the hit rate of the novel and repurposed drug for Ebola therapy. Additionally, the time and cost of wet laboratory experiments can be drastically reduced by the support of bioinformatics approach. Our laboratory has succeeded not only in creating the bioinformatics research pipeline but also screening and developing the drug candidate to cure Ebola. Through pharmacophore-based virtual screening and molecular docking simulations, we discovered that about three Indonesian natural product compounds have noteworthy molecular interactions against EBOV VP35 protein, which are responsible for the RNA synthesis of the Ebola. These compounds can be reevaluated further through advances in in silico simulation and in vitro experiments.

show abstract

Section: Introductionmentioning

confidence: 99%

“…It mainly affected Nzara, Maridi, Tembura, and Juba where 150 of 284 victims died (the mortality rate of 53%) [2,23]. After the first outbreak, 19 other outbreaks have occurred in Africa with the mean fatality rate of 65.4% [11].…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics Approach to Screening and Developing Drug against Ebola

Tambunan¹,

Alkaff²,

Nasution³

2018

Advances in Ebola Control

View full text Add to dashboard Cite

show abstract

“…1 It first appeared in Africa in the year 1976, since then this virus and other genetically similar species have been involved in over 25 outbreaks in both central and western parts of Africa. [2][3][4] The recent 2014 West African outbreak has been the more devastating of them both in terms of death rate and wide spread transmission. Cumulatively it has resulted in over 22, 495 cases and 8981 deaths out of which 495…”

Section: Introductionmentioning

confidence: 99%

Predictors of knowledge regarding Ebola virus disease among medical and nursing students in a Nigerian teaching hospital

Balami

Suriani

Saliluddin

et al. 2016

Int J Community Med Public Health

View full text Add to dashboard Cite

“…M embers of the filovirus and flavivirus families are the causative agents of life-threatening diseases. Ebola virus (EBOV), a filovirus, causes hemorrhagic fever with an average case fatality rate as high as 65% (1). Although there are EBOV vaccine candidates (2,3), there is currently no licensed vaccine or treatment.…”

mentioning

confidence: 99%

Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses

Richard

Zhang

Park

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

116

105

View full text Add to dashboard Cite

Phosphatidylserine (PS) receptors contribute to two crucial biological processes: apoptotic clearance and entry of many enveloped viruses. In both cases, they recognize PS exposed on the plasma membrane. Here we demonstrate that phosphatidylethanolamine (PE) is also a ligand for PS receptors and that this phospholipid mediates phagocytosis and viral entry. We show that a subset of PS receptors, including T-cell immunoglobulin (Ig) mucin domain protein 1 (TIM1), efficiently bind PE. We further show that PE is present in the virions of flaviviruses and filoviruses, and that the PE-specific cyclic peptide lantibiotic agent Duramycin efficiently inhibits the entry of West Nile, dengue, and Ebola viruses. The inhibitory effect of Duramycin is specific: it inhibits TIM1-mediated, but not L-SIGNmediated, virus infection, and it does so by blocking virus attachment to TIM1. We further demonstrate that PE is exposed on the surface of apoptotic cells, and promotes their phagocytic uptake by TIM1-expressing cells. Together, our data show that PE plays a key role in TIM1-mediated virus entry, suggest that disrupting PE association with PS receptors is a promising broad-spectrum antiviral strategy, and deepen our understanding of the process by which apoptotic cells are cleared. M embers of the filovirus and flavivirus families are the causative agents of life-threatening diseases. Ebola virus (EBOV), a filovirus, causes hemorrhagic fever with an average case fatality rate as high as 65% (1). Although there are EBOV vaccine candidates (2, 3), there is currently no licensed vaccine or treatment. Dengue virus (DENV) and West Nile virus (WNV) belong to the flavivirus family. Both are transmitted to humans through mosquito bites and can cause lethal hemorrhagic fever (in the case of DENV) or severe neurological diseases (in the case of WNV) (4, 5). Flaviviruses are emerging as major health concerns in tropical and subtropical areas worldwide. More than one third of the world's population is estimated to be at risk for DENV infection, with approximately 400 million people infected yearly (6). There are currently no approved vaccines or therapeutic agents against DENV or WNV.Virus entry into host cells typically initiates with the interaction between viral entry glycoproteins (GPs) and a receptor or coreceptor expressed at the surface of the target cell. Viruses also use less specific mechanisms to localize to target cell membranes, for example through GP association with various attachment factors (7). During the past few years, it has been increasingly recognized that many viruses also use a strategy known as apoptotic mimicry to promote their association with, and internalization into their target cells (8). Receptors for phospholipids, specifically phosphatidylserine (PS), normally involved in the clearance of apoptotic cells, markedly enhance the infection of a number of enveloped viruses. These PS receptors are presumed to engage PS on the virion membrane rather than the viral entry protein (9, 10). Enveloped viruses acquire...

show abstract

Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data

Cited by 87 publications

References 13 publications

Bioinformatics Approach to Screening and Developing Drug against Ebola

Bioinformatics Approach to Screening and Developing Drug against Ebola

Predictors of knowledge regarding Ebola virus disease among medical and nursing students in a Nigerian teaching hospital

Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses

Contact Info

Product

Resources

About